Open AccessCCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis
Author(s) -
Ari M. Goldminz,
Mayte SuárezFariñas,
Andrew C. Wang,
Nicole Dumont,
James G. Krueger,
Alice B. Gottlieb
Publication year - 2015
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2015.0452
Subject(s) - adalimumab , medicine , methotrexate , psoriasis , psoriasis area and severity index , infliximab , dermatology , gastroenterology , tumor necrosis factor alpha
Methotrexate is a first-line systemic agent for treating of psoriasis, although its onset of effects is slower and overall it is less effective than tumor necrosis factor blockers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom